Alzheimer’s Blood Test for Early Detection

MedDevice by Design with Mark Drlik and Ariana Wilson
Resources

Alzheimer’s Blood Test for Early Detection

Sector: Diagnostics
YouTube video thumbnail

In this episode of MedDevice by Design, we explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.

A Simpler Diagnostic Pathway

Traditionally, Alzheimer’s diagnosis has required expensive imaging or invasive cerebrospinal fluid collection. This new approach allows patients to have their blood drawn at a standard medical office, with labs analyzing the sample for specific biomarkers. If these proteins are detected, the patient may then be referred for confirmatory tests and begin treatment earlier.

Supporting Earlier Treatment and Better Research

Early detection is crucial for effective treatment. Many Alzheimer’s drugs are more beneficial when administered during the disease’s early stages. This blood test can identify potential patients sooner, improving clinical outcomes. It also helps pharmaceutical companies recruit participants for trials and monitor drug efficacy over time.

Barriers to Widespread Use

While promising, the Alzheimer’s blood test still faces some hurdles. It’s currently a laboratory-developed test (LDT) and has not yet received FDA approval. Because of this, it’s often not covered by insurance and remains a costly out-of-pocket option for most people.

A Look Ahead

The potential impact of this innovation is immense. By making early Alzheimer’s detection more accessible, the test could transform clinical care and research. As approval processes advance and accessibility improves, this technology may reshape how we diagnose and treat neurodegenerative conditions.

Engineer reviewing a colorful mind map diagram across dual monitors and laptop while collaborating with a remote team on a video call during an online whiteboard risk analysis session

Graphical mind maps created in online whiteboards offer a low-barrier, highly collaborative approach to early risk analysis in medical device development.

Product designer sketching early-phase concept wireframes on glass whiteboard during ideation session

Early phase concept development is a weird part of a project lifecycle. It is often the most exciting phase, because the team is exploring possibilities, generating new ideas, and turning a fuzzy opportunity into something real.

Engineer in cleanroom assembling precision medical device prototype with optical components

Clinical prototypes must not only function as intended, but also be manufactured, documented, and supported in a way that satisfies regulatory expectations and clinical realities.

GLP-1 injection pen showing daily vs weekly dosing comparison

In this Bio Break episode, Nick and Nigel explore why some GLP-1 drugs are taken daily while others last a full week, and what drives that difference at a molecular level.